Nam
et al. [96]; Microarray with 377 (314 human) mirVana miRNA probes (Ambion) |
Samples: 20 serous ovarian cancer tissues: 9 chemo-resistant, 11 chemo-sensitive tumors; Controls: 8 normal ovarian tissues |
Increased expression of miR-200a, 200b, 200c and 141 in tumor samples
vs. normal tissue |
High expression of miR-200a, 200b, 200c and 141 were significantly correlated with decreased progression-free survival as well as overall survival |
Hu
et al. [97]; qRT-PCR miRNA assays (Applied Biosystems) |
55 patients: 48 epithelial ovarian carcinomas and 7 primary peritoneal carcinomas |
Disease recurrence and poor overall survival were associated with low miR-200a, 200b and 429 expression |
miR-200b-429 cluster expression has prognostic value in EOC |
Eitan
et al. [98]; Custom microarray slide (Nexetrion®) with 900 miRNA probes |
57 patients who had undergone surgery for tumor resection: 19 Stage I patients, 38 Stage III patients; All received platinum based chemotherapy |
miR-200a expression was higher in Stage I ovarian cancer compared to Stage II |
The data set shows significantly higher expression of miR-200a in early stage disease correlating with improved survival |
Marchini
et al. [89]; G4470B human miRNA microarray (Agilent Technologies) with probes for 723 human miRNAs |
144 patients with Stage I EOC out of which 29 patients relapsed |
Tumors with lower miR-200c levels seen in patients who relapsed |
miR-200 expression could be used as an indication of relapse in Stage I tumors |
Leskela
et al. [88]; qRT-PCR using the miRCURY™ LNA miRNA assay kits (Exiqon) |
72 patients were studied for overall survival analysis; A subgroup of 57 patients with both advanced tumor stage and serous carcinoma histotype were studied for treatment response |
miR-200 expression correlated with β-Tubulin III levels |
Low miR-200 expression was seen in patients without complete response to paclitaxel when compared to patients with complete response; Low miR-200 expression had a trend towards poor survival |